• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

    6/30/21 8:30:00 AM ET
    $BGNE
    $LEGN
    $MTEM
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGNE alert in real time by email

    NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director.

    "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeutics for patients who have no other treatment options," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.

    Dr. Sanders most recently served as strategic advisor to the Chief Medical Officer (CMO) of Celgene, following Celgene's acquisition of Juno where she was an Executive Vice President of Development Operations. She also served as Transition Advisor to Bristol Myers Squibb (BMS), which acquired Celgene. In those roles, she ensured the effective integration of Juno's Chimeric Antigen Receptor T (CAR-T) Cell Development Organization into the Celgene and BMS organizations. Prior to that, Dr. Sanders held numerous leadership positions over the course of 23 years at Genentech/Roche, including serving as Senior Vice President, Global Head of Clinical Operations and Industry Collaboration, for six years.

    "The ability to quickly develop effective medicines is critically important in rare diseases, where patients have few or no treatment options," said Dr. Sanders. "I am thrilled to join the Ultragenyx Board and support the executive team as it works diligently to make a significant impact on these patient populations."

    Currently, Dr. Sanders serves as a member of the Board of Directors of several biotechnology companies including Beigene Ltd. (NASDAQ:BGNE), Molecular Templates Inc. (NASDAQ:MTEM), Legend Biotech Corporation (NASDAQ:LEGN), and AltruBio (formerly AbGenomics) Inc. She is a member of the Board of Trustees and Chair of the Research Ethics Committee for the Fred Hutchinson Cancer Research Center, a non-profit cancer research organization in Seattle. Dr. Sanders graduated magna cum laude from the University of the Philippines where she earned a B.S. and M.S. in statistics. She also earned an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.

    About Ultragenyx Pharmaceutical Inc.

    Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

    The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

    For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

    Contact Ultragenyx Pharmaceutical Inc.

    Investors & Media

    Joshua Higa

    415-475-6370



    Primary Logo

    Get the next $BGNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGNE
    $LEGN
    $MTEM
    $RARE

    CompanyDatePrice TargetRatingAnalyst
    Ultragenyx Pharmaceutical Inc.
    $RARE
    5/28/2025Outperform
    William Blair
    BeiGene Ltd.
    $BGNE
    12/3/2024$300.00Overweight
    Morgan Stanley
    Legend Biotech Corporation
    $LEGN
    10/8/2024$86.00Buy
    Redburn Atlantic
    BeiGene Ltd.
    $BGNE
    9/18/2024$288.00Mkt Outperform
    JMP Securities
    Legend Biotech Corporation
    $LEGN
    6/17/2024$88.00Buy
    Truist
    Ultragenyx Pharmaceutical Inc.
    $RARE
    6/6/2024$56.00 → $67.00Neutral → Buy
    Goldman
    Legend Biotech Corporation
    $LEGN
    5/24/2024$86.00 → $73.00Buy
    H.C. Wainwright
    Legend Biotech Corporation
    $LEGN
    5/23/2024$60.00Buy
    Deutsche Bank
    More analyst ratings